Menlo Park, CA, United States of America

Kirsten Angela Macfarlane


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Kirsten Angela Macfarlane: Innovator in Ophthalmic Treatments

Introduction

Kirsten Angela Macfarlane is a prominent inventor based in Menlo Park, California. She has made significant contributions to the field of ophthalmology, particularly in the treatment of meibomian gland dysfunction. With a total of five patents to her name, her work has garnered attention for its innovative approaches to eye care.

Latest Patents

Among her latest patents, Kirsten has developed compositions and methods for the treatment of meibomian gland dysfunction. These compositions include keratolytic agents such as salicylic acid and selenium disulfide. The topical administration of these compositions to the eyelid margin or surrounding areas provides therapeutic benefits to patients suffering from this condition. Her work in this area highlights her commitment to improving patient outcomes through innovative solutions.

Career Highlights

Kirsten is currently associated with Azura Ophthalmics Ltd., where she continues to advance her research and development efforts. Her expertise in ophthalmic treatments has positioned her as a key figure in the industry. She has successfully translated her research into practical applications that benefit patients.

Collaborations

Kirsten has collaborated with notable colleagues, including Omer Rafaeli and Shimon Amselem. These partnerships have further enhanced her research and contributed to the development of effective treatments in her field.

Conclusion

Kirsten Angela Macfarlane is a trailblazer in the field of ophthalmology, with a focus on innovative treatments for meibomian gland dysfunction. Her contributions through patents and collaborations reflect her dedication to improving eye care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…